Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1256

1.

Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.

Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.

Int J Gynecol Cancer. 2013 Mar;23(3):513-8. doi: 10.1097/IGC.0b013e318280f3bc.

PMID:
23334437
2.

Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.

Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, Prendiville WJ.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008054. doi: 10.1002/14651858.CD008054.pub2. Review.

PMID:
23543559
3.

Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.

Waldstrøm M, Christensen RK, Ørnskov D.

Cancer Cytopathol. 2013 Mar;121(3):136-45. doi: 10.1002/cncy.21233. Epub 2012 Sep 17.

4.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
5.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
6.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
7.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
8.

Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results.

Cohen D, Austin RM, Gilbert C, Freij R, Zhao C.

Am J Clin Pathol. 2012 Oct;138(4):517-23.

PMID:
23010706
9.

Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.

Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, Woodward L.

J Fam Pract. 1998 Feb;46(2):136-41.

PMID:
9487319
10.

Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.

Verdoodt F, Szarewski A, Halfon P, Cuschieri K, Arbyn M.

Cancer Cytopathol. 2013 Dec;121(12):675-87. doi: 10.1002/cncy.21325. Epub 2013 Jul 23. Review.

11.

Comparison of the clinical performance of an HPV mRNA test and an HPV DNA test in triage of atypical squamous cells of undetermined significance (ASC-US).

Waldstrom M, Ornskov D.

Cytopathology. 2012 Dec;23(6):389-95. doi: 10.1111/j.1365-2303.2011.00923.x. Epub 2011 Sep 20.

PMID:
21933290
12.

Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing.

Eltoum IA, Chhieng DC, Crowe DR, Roberson J, Jin G, Broker TR.

Cancer. 2007 Jun 25;111(3):154-9.

13.

APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.

Stoler MH, Wright TC Jr, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C.

Am J Obstet Gynecol. 2013 Feb;208(2):144.e1-8. doi: 10.1016/j.ajog.2012.12.003. Epub 2012 Dec 5.

PMID:
23220509
14.

Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.

Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J, Taddeo FJ, Burchette RJ, Qiao YL.

Int J Cancer. 2010 Sep 1;127(5):1151-7. doi: 10.1002/ijc.25144.

15.
16.

HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.

Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ.

BMC Cancer. 2016 Nov 28;16(1):922.

17.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
18.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

19.

An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China.

Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE.

Cancer Prev Res (Phila). 2013 Sep;6(9):938-48. doi: 10.1158/1940-6207.CAPR-13-0091. Epub 2013 Jul 22.

20.

Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer.

Huang TH, Lai HC, Liu HW, Lin CJ, Wang KH, Ding DC, Chu TY.

Int J Gynecol Cancer. 2010 May;20(4):513-9. doi: 10.1111/IGC.0b013e3181c7fe6e.

PMID:
20442585

Supplemental Content

Support Center